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Abstract
Background: Human prostate basal cells expressing alpha-6 integrin (CD49f
Hi) and/or CD44 form prostaspheres in vitro. This
functional trait is often correlated with stem/progenitor (S/P) activity, including the ability to self-renew and induce
differentiated tubules in vivo. Antigenic profiles that distinguish tubule-initiating prostate stem cells (SCs) from progenitor
cells (PCs) and mature luminal cells (LCs) with less regenerative potential are unknown.
Methodology/Principle Findings: Prostasphere assays and RT-PCR analysis was performed following FACS separation of
total benign prostate cells based upon combinations of Epcam, CD44, and/or CD49f expression. Epithelial cell fractions were
isolated, including Epcam
+CD44
+ and Epcam+CD44+CD49f
Hi basal cells that formed abundant spheres. When non-sphere-
forming Epcam
+CD44
2 cells were fractionated based upon CD49f expression, a distinct subpopulation (Ep-
cam
+CD44
2CD49f
Hi) was identified that possessed a basal profile similar to Epcam
+CD44
+CD49f
Hi sphere-forming cells
(p63
+AR
LoPSA
2). Evaluation of tubule induction capability of fractionated cells was performed, in vivo, via a fully humanized
prostate tissue regeneration assay. Non-sphere-forming Epcam
+CD44
2 cells induced significantly more prostate tubular
structures than Epcam
+CD44
+ sphere-forming cells. Further fractionation based upon CD49f co-expression identified
Epcam
+CD44
2CD49f
Hi (non-sphere-forming) basal cells with significantly increased tubule induction activity compared to
Epcam
+CD44
2CD49f
Lo (true) luminal cells.
Conclusions/Significance: Our data delineates antigenic profiles that functionally distinguish human prostate epithelial
subpopulations, including putative SCs that display superior tubule initiation capability and induce differentiated ductal/
acini structures, sphere-forming PCs with relatively decreased tubule initiation activity, and terminally differentiated LCs that
lack both sphere–forming and tubule-initiation activity. The results clearly demonstrate that sphere-forming ability is not
predictive of tubule-initiation activity. The subpopulations identified are of interest because they may play distinct roles as
cells of origin in the development of prostatic diseases, including cancer.
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Introduction
Human adult prostate S/Ps are characterized by surface marker
expression, as well as functional traits, including the ability to self-
renewalanddifferentiateintomultiplelineages[1,2,3,4,5].Markers
that have been utilized to isolate human prostate S/Ps include
Trop2, CD44, alpha2beta1-integrin
Hi, alpha6-integrin
Hi (CD49f),
andCD133[1,2,4,6].However,aconsensusdoesnotexistregarding
the antigenic profile of a functionally pure human prostate SC
populationandhowtodistinguishmultipotenttubule-initiatingSCs
from progenitors with more limited potential. Making such a
distinction may have important implications in understanding the
etiology ofprostatic disease,includingbenignprostatichypertrophy
and cancer.
Sphere-forming cells isolated from dissociated primary tissues
are enriched in S/P cells in multiple organ systems [7,8,9,10]. In
the human prostate, sphere-forming capability enables the
selection of a subpopulation of epithelial cells with SC-like traits,
including self-renewal and the ability to differentiate into tubular
structures when implanted into immunocompromised mice [1,4].
Previous studies evaluating the antigenic profile of cells capable of
forming prostaspheres indicate that they reside within the basal
layer of normal prostatic ducts [1,4,11,12]. onsequently, the
combination of Trop2 and CD49f
Hi expression enables isolation of
the basal cell fraction (Trop2
+CD49f
Hi), which exclusively forms
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transformation after genetic manipulations [1,4,6]. Sphere-form-
ing cells are rare in prostate subpopulations that display luminal
profiles (Trop2
+CD49f
Lo or Trop2
+CD44
2)[1,4].
Subdivision of the basal population and enrichment of a sphere-
forming and/or tubule-regenerating SC population has yet to be
accomplished. However, a functional delineation of the human
prostate cellular hierarchy, in addition to basal/luminal profile,
could provide more specific insight about the cells of origin for
prostate cancer and the pathways utilized by normal SCs that may
become corrupted in prostate disease. The aim of this work is to
employ in vitro sphere culture and in vivo tissue regeneration
assays to interrogate combinations of surface antigens that may
further subdivide human prostate epithelial cells and enable
functional separation of tubule-initiating SCs from progenitors
with more limited capabilities. In this report, we accomplish these
goals by incorporating a refined tissue regeneration assay, in which
human fetal prostate stroma (hFPS) is utilized to induce tubule
formation/differentiation in a fully humanized system. Our results
demonstrate that the combination of Epithelial Cell Adhesion
Molecule (Epcam), CD44, and CD49f can be used to isolate three
distinct populations: (i) a putative prostate SC population that does
not form spheres, but induces relatively robust tubule regenera-
tion, (ii) PCs possessing maximal sphere-forming ability, but
decreased tubule-initiation capability, and (iii) terminally differen-
tiated LCs that lack both sphere-forming and tissue regenerating
potential. The uncoupling of sphere-forming and tubule-initiating
functions indicates that human prostate cells with the most
potential for niche interaction and tubule development appear to
be quiescent in sphere-forming culture conditions.
Results
Epcam and CD44 enable separation of prostate cell
lineages.
Epcam/Trop1 is a pan-epithelial antigen that is also expressed
on most carcinomas, including prostate cancer [13]. In benign
human prostate, immunohistochemical (IHC) staining demon-
strates confinement of Epcam expression to epithelial cells that
compose prostate ducts and acini (Figure 1A). CD44 is a single
pass transmembrane glycoprotein involved in cell-cell matrix
adhesion, cell signaling, inflammation, and cell migration ([14]). In
the benign human prostate, CD44 marks basal cells and rare
neuroendocrine cells [15]. Based on the expression pattern of
Epcam and CD44 observed in IHC analysis of benign prostate
tubules, it appears that Epcam
+CD44
+ cells compose the basal
layer, while Epcam
+CD44
2 cells appear predominantly luminal
(Figure 1A). We hypothesized that fractionating total prostate cells
based upon the combination of Epcam and CD44 expression
profiles could be a first step in determining antigenic profiles that
delineate human prostate cellular hierarchy, by enabling basal and
luminal separation. An advantage of both Epcam and CD44 is
that conjugated magnetic beads are readily available that enable
rapid fractionation of prostate cells without the need for a cell
sorter. This may increase the accessibility and feasibility of
fractionating surgical specimens. FACS analysis of total prostate
epithelial cells using fluorescent antibodies to detect Epcam and
CD44 expression demonstrate clear separation of (Epcam
+)
epithelial cells from (Epcam
2) stromal/blood cells (Figure 1B).
Although FACS analysis demonstrates that separation based on
CD44 expression is not as distinct as Epcam, both CD44
+ and
CD44
2 fractions were obtained via cell sorting or magnetic beads
separation (Figure 1B).
Expression of basal- and luminal-specific genes correlates
with Epcam/CD44 status.
Prostate basal and luminal cells can be distinguished based on
marker profile, in addition to architectural organization. The
tumor protein p63 is a hallmark indicator of basal cells, which also
express relatively low levels of AR and PSA [16,17]. On the other
hand, luminal cells lack p63, but express strong levels of AR, PSA,
and cytokeratin 8 (CK8) [18,19]. In order to confirm enrichment
of basal and luminal cells after fractionation based on Epcam/
CD44 expression, quantitative RT-PCR analysis was performed
on total RNA isolated from fractionated cells with primers
targeting basal-specific and luminal-specific genes (Figure 1C).
Compared to unfractionated cells and the Epcam
+CD44
+ fraction,
Epcam
+CD44
2 cells demonstrated significantly increased expres-
sion of AR, PSA, and CK8 with low relatively low expression of
the basal marker, p63. On the other hand, Epcam
+CD44
+ cells
demonstrated virtually undetectable AR, PSA, and CK8 and
enhanced expression of p63. These results are compatible with the
known expression profiles of basal and luminal cells and indicate
that the combination of Epcam and CD44 can effectively enrich
for these lineages [19,20].
We have previously shown that prostate S/P cells are capable of
prostasphereformationinvitro[4].Additionally,wehavefoundthat
basal cells are exclusively capable of forming spheres [1]. Therefore
sphere-forming capability of Epcam
+CD44
+ and Epcam
+CD44
–
cell fractions was evaluated in comparison to unfractionated (U)
cells. Consistent with previous studies, virtually all of the sphere-
forming cells were confined to the basal-enriched Epcam
+CD44
+
cell fraction (Figure 1D), and this fraction demonstrated a 3-fold
increase in sphere-forming cells compared to unfractionated total
prostate cells. This data suggests that Epcam/CD44 fractionation
enables a functional segregation of epithelial cell populations, in
addition to basal and luminal separation.
HFPS Supports Prostate Tissue Regeneration Induced by
Adult Human Prostate Cells In Vivo.
We have previously described regeneration of human prostate
tissuefollowingimplantationofadultprostatecells(orprostaspheres)
combined with rat urogenital sinus mesenchyme (rUGSM) and
MatrigelH into Non-Obese Diabetic Severely Combined Immuno-
deficient mice that are Interluekin-2 Receptor Null (SCID-
NOD
IL2grNULL) [4,6]. In an effort to employ a fully humanized
prostate tissue regeneration system, rUGSM was replaced with
humanprostatestromalcellsculturedfromdissociatedfetalprostate
tissue (Figure 2). Histological evaluation of fetal prostate specimens
demonstrates abundant stroma surrounding the prostatic urethra
with developing epithelial buds/tubules (Figure 2A). FBS-supple-
mented culture media supported the outgrowth of a nearly pure
(Epcam-negative) human fetal stromal cell population (hFPS) that
could be passaged continuously for more than 10 generations
(Figure2Banddatanotshown).CryopreservationofhFPS,followed
bythawandre-cultureenabledfurtherexpansionofthesecellsprior
to use in vivo. When hFPS was combined with freshly isolated adult
prostate epithelial cells (Figure 2C) or sphere-forming cells (data not
shown) and MatrigelH, followed by subcutaneous implantation into
SCID-NOD
IL2grNULLmice,epithelialcord-likestructuresformedas
early as 6 weeks(data not shown). Fully differentiated ductal/acinar
structures with PSA-expressing luminal cells were prominent by
6 months (Figure 2C). Epithelial cords and/or tubular structures
failed to form if MatrigelH and hFPS were recombined in the
absence of prostate epithelial cells (Figure S1). No differences in
tubule development were noted in grafts induced by rUGSM or
hFPS (Figure S1). All structures typically identified in benign
Prostate Sphere Formation versus Tubule Initiation
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including epithelial cords, corporal amylacea, and secretion-filled
ducts/acini. Layers of epithelial cells expressing basal markers (K5,
P63),luminalmarkers(K8,AR,PSA),oracombinationofbothwere
also identified (Figure 2C). HFPS was generated from 6 different
fetal specimens and all demonstrated similar growth in culture,
FACS profile, and ability to support tubular outgrowth when
combined with adult prostate epithelial cells (data not shown).
Tubule initiating capability is prevalent in the non-
sphere-forming Epcam
+CD44
2 luminal-enriched cell
fraction.
Although sphere formation is a common feature of S/Ps, one
critical characteristic that prostate SCs must demonstrate is the
ability to induce new tubule formation inclusive of ducts/acini
composed of both basal and luminal cells. Prostate tissue
regeneration assays have been utilized to interrogate the tubule
initiation capability of putative S/P populations in mouse and
human [4,21,22]. In these assays, total or fractionated cells
obtained from fetal or adult prostate tissues are combined with
supportive stroma (i.e., UGSM) followed by sub-renal implanta-
tion as a collagen graft or subcutaneous implantation with
MatrigelH into immunocompromised mice. Cell fractions that
possess S/P activity induce multi-layered tubular outgrowths with
secretions surrounded by stroma. We have previously shown that
sphere-forming cells as well as basal cells isolated based on co-
expression of Trop2 and high levels of CD49f have an increased
Figure 1. Variation in expression of Epcam and CD44 enables separation of distinct populations of prostate cells from dissociated
surgical specimens. A. Immunohistochemical analysis of Epcam and CD44 expression in benign human prostate tissue specimens (206
magnification). B. FACS analysis of Epcam and CD44 expression in total prostate cells isolated from dissociated benign human prostate tissue. Total
prostate cells stained with Epcam-PE and CD44-FITC conjugated antibodies prior to FACS analysis. C. Epcam
+CD44
+ and Epcam
+CD44
2 fractions
display basal (P63+) and luminal (CK8+,A R +, PSA+) profiles, respectively. Quantitative RT-PCR reactions were performed in triplicate with a minimum
of 3 individual patient specimens. Black columns represent Unfractionated (U) cells, red columns represent Epcam
+CD44
+ cells (+/+), and blue
columns represent Epcam
+CD44
2 cells (+/2). D. Unfractionated prostate epithelial cells isolated from benign prostate tissue specimens or cells
fractionated based on Epcam/CD44 expression were evaluated for sphere-forming capability in vitro. 1610
4 cells were plated in semi-solid (MatrigelH)
cultures. Approximately 14 days after seeding, prostaspheres were quantitated in all wells and the percentage of sphere-forming cells was calculated
in each fraction. All experiments were performed in triplicate, using a minimum of three individual patient samples. Statistical analysis was performed
using standard one-way ANOVA analysis; P,0.05(*), P,0.01(**).
doi:10.1371/journal.pone.0034219.g001
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+CD49f
Lo)
cells [1,4,6].
In order to investigate the ability of cells fractionated based
upon Epcam/CD44 expression to form tubules in vivo, human
prostate tissue regeneration was performed. Approximately 1610
5
unfractionated cells, Epcam
+CD44
+ cells, or Epcam
+CD44
2cells
were combined with 2610
5 hFPS and MatrigelH, followed by
subcutaneous implantation into SCID-NOD
IL2grNULL mice.
Approximately twelve weeks following implantation, grafts were
harvested and analyzed for tubule induction via histological
analysis of paraffin embedded sections (Figure 3A). A table
containing the rate of engraftment of unfractionated and
fractionated cells is shown in Figure S2. Tubular structures were
identified in grafts that developed from unfractionated cells and in
Epcam
+CD44
+ recombinant grafts. Surprisingly, the Ep-
cam
+CD44
2 luminal enriched/non-sphere-forming fractions
yielded the largest number of tubular structures (Figure 3A and
3C). All grafts demonstrated a range of epithelial cord-like
structures and more fully developed tubules with secretion-filled
lumens (Figure 3A). Immunohistochemical staining confirmed the
presence of basal (p63
+) and luminal (CK8
+) cells in regenerated
tubules (Figure 3B). Although FACS and cytospin examination of
fractionated cells confirmed CD44
2 status (data not shown),
CD44
+ cord-like structures and tubules containing a distinct
CD44
+ basal layer were identified in mature grafts induced by
Epcam
+CD44
2 cell fractions (Figure 3B). This data suggests that
Epcam
+CD44
2 cells may be precursors for Epcam
+CD44
+ cells
found in regenerated tubular structures.
A functional role for a non-sphere-forming/luminal-enriched
fraction appeared to contradict prior published results, in which
fractionation of luminal cells based on Trop2/CD49f expression
displayed no functional capabilities in vitro and in vivo[6]. To
Figure 2. Isolation of human fetal prostate stroma (hFPS) for use in prostate tissue regeneration assays. A. Gross specimen containing
17-week fetal bladder (FB), prostate (FP), and urethra (U) en block with adjacent panel showing transverse hematoxylin and eosin (H&E) stained
histological section. Developing prostate glands budding from the prostatic urethra are surrounded by abundant stroma. B. HFPS cells are cultured in
DMEM supplemented with FBS. FACS analysis of cultured hFPS cells using antibodies that target Epcam demonstrates lack of (Epcam+) epithelial cell
outgrowth. C. Regenerated graft induced by hFPS after recombination with freshly isolated adult human prostate cells and MatrigelH, followed by
subcutaneous injection. H&E staining of paraffin-embedded graft demonstrates tubules with a distinct basal layer, containing cells that express tumor
protein 63 (P63+) but lack luminal cell marker expression, including Androgen Receptor (AR), cytokeratin 8 (CK8), and Prostate Specific Antigen (PSA).
A luminal layer is identified in the majority of outgrowths and contains cells that are P632,A R +, CK8+, and PSA+. The bottom panel displays the
different types of outgrowths identified in recombinant grafts, including epithelial cords (EC), corpora amylacea (CA), and epithelial cords/buds (EC).
doi:10.1371/journal.pone.0034219.g002
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Trop2 expression was performed to evaluate co-expression of
these surface markers. Indeed, there appeared to be almost
complete overlap in expression of Trop2 and Epcam, with
virtually all Trop2
+ cells co-expressing Epcam (Figure S3A). On
the contrary, high expression CD49f did not appear to be confined
to the CD44+ population, since a fraction of CD44
2 cells were
CD49f
Hi (Figure S3B). This result suggests that Epcam
+CD44
2
prostate cells may be further subdivided based upon CD49f
expression and may explain differential functional capabilities of
basal/luminal cell fractions isolated based on Epcam/CD44
profile compared to Trop2/CD49f.
CD49f enables functional delineation of putative SCs,
PCs, and LCs.
As described above, previous studies indicated that
Trop2
+CD49f
Hi basal cells display both sphere forming and
tubule regenerating capabilities, compared to the Trop2
+CD49f
Lo
luminal cells, which lack these functional capabilities [4,6]. Given
the surprising result that luminal-enriched Epcam
+CD44
2 cells
display predominant tubule-initiation activity, we investigated
whether or not CD49f
Hi cells present within this subpopulation
may be responsible for tubule initiation in vivo. FACS analysis was
performed on total prostate cells after incubation with antibodies
targeting Epcam, CD44, and CD49f. Both CD49f
Hi and CD49f
Lo
subpopulations were identified in Epcam
+CD44
+ and Ep-
Figure 3. Tubule formation induced by unfractionated and fractionated (Epcam
+CD44
+ and Epcam
+CD44
–) prostate cells in human
prostate tissue regeneration assays. A. H&E stained sections of paraffin-embedded 12-week grafts harvested from SCID-NOD
IL2crNULL mice.
Unfractionated (U) total prostate cells or Epcam
+CD44
+ and Epcam
+CD44
2 cell fractions combined with human fetal prostate stromal cells and
MatrigelH were implanted subcutaneously into male SCID-NOD
IL2crNULL mice. Testosterone was supplemented via pellets inserted subcutaneously. B.
Example of secretion-filled ducts that display basal (p63 positive) and luminal (CK8 positive) cells induced by Epcam
+CD44
2 prostate cell fractions.
Tubules and epithelial developed from cords containing CD44
+ cells also developed from the CD44
– cell fraction. C. Comparison of the number of
tubular structures identified in unfractionated, Epcam
+CD44
+, and Epcam
+CD44
2 grafts. After paraffin embedding, sections were made throughout
the grafts. The two representative sections containing the highest number of tubules were identified and all tubules present in the low power (4X
magnification) field were quantitated. The average numbers of tubules from total grafts obtained from unfractionated or fractionated cells are
complied for the graph. Statistical analysis was performed using standard one-way ANOVA analysis; P, 0.001 (***).
doi:10.1371/journal.pone.0034219.g003
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+CD44
2 fractions (Figure 4A and S4). Cell sorting enabled
isolation of prostate cells based upon Epcam/CD44/CD49 status.
Prostasphere culture of Epcam
+CD44
+CD49f
Hi cells demonstrat-
ed enrichment of sphere-forming capability (10-fold over unfrac-
tionated cells and 3-fold over Epcam
+CD44
+ cells) with 40–50% of
cells within this fraction capable of forming spheres (Figure 4B).
On the other hand, less than 1% of Epcam
+CD44
+CD49f
Lo or
Epcam
+CD44
2CD49f
Hi cells were able to form spheres (Figure 4B
and data not shown, respectively).
In order to evaluate tubule initiation activity of Epcam
+CD44
2
non-sphere-forming cells subdivided by CD49f, in vivo tissue
regeneration with hFPS was employed (Figure 4C). Recombinant
grafts were retrieved from Epcam
+CD44
2CD49f
Hi cell fractions
containing significantly more tubules than those induced by
Epcam
+CD44
2CD49f
Lo cells (Figure 4C). FACS analysis of
dissociated grafts induced by Epcam
+CD44
2CD49f
Hi cells
demonstrated a similar composition of cells (based on Epcam/
CD44/CD49f expression) as the original prostate surgical
specimen (Figure 4E), indicating that this minority population
could induce an intact prostate tissue profile.
As previously described, bright CD49f expression is associated
with a basal cell profile, therefore, Epcam
+CD44
2CD49f
Hi and
Epcam
+CD44
2CD49f
Lo cell fractions were evaluated by RT-PCR
analysis to determine if the original Epcam
+CD44
2 fraction
containedamixofluminalandbasalcells[4,6,11].RNAexpression
of p63 in association with a lack of AR and PSA indicated that
Epcam
+CD44
2CD49f
Hi cells possessed a basal profile, while
Epcam
+CD44
2CD49f
Lo cells exhibited a luminal profile, demon-
strated by significant AR and PSA expression (Figure S5). This
contrasting expression profile of Epcam
+CD44
2CD49f
Hi cells
compared to RT-PCR analysis of Epcam
+CD44
2 cells (in which
fractionation with CD49f was not performed), indicates that the
Figure 4. Identification and functional evaluation of CD49f
Hi/Lo cells present in Epcam
+CD44
+ and Epcam
+CD44
2 fractions. A. FACS
analysis of Epcam
+CD44
+ and Epcam
+CD44
2for CD49f
Hi expression, with functionally distinct populations annotated. B. Sorting of Epcam
+CD44
+
based on CD49f expression followed by sphere analysis in vitro (***P,0.001). Unfractionated (U), Epcam
+CD44
+ (+/+), Epcam
+CD4+
iCD49f
Hi (+/+/H),
Epcam
+CD44
+CD49f
Lo (+/+/L). C. Sorting of Epcam
+CD44
2 based on CD49f expression followed by quantification of tubule initiation in vivo. After
paraffin embedding, sections were made throughout the grafts. The two representative sections containing the highest number of tubules (46
magnification) were identified and quantitated. The average number of tubules from all the grafts retrieved is represented in the bar graph
(**P,0.01). Epcam
+CD442CD49f
Hi (+/2/H), Epcam
+CD44
2CD49f
Lo (+/2/L). D. FACS analysis of total cells obtained from three grafts induced by the
Epcam
+CD44
2CD49f
Hi cell fraction. Grafts were mechanically and enzymatically digested to retrieve single cells that were pooled for FACS analysis.
Although only highly enriched Epcam
+CD44
2CD49f
Hi cell fractions were combined with hFPS and Matrigel prior to injection, all of the cell types
identified in the original prostate surgical specimens were found in regenerated tissue grafts.
doi:10.1371/journal.pone.0034219.g004
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+CD44
2 cell
fractions was likely due to a masking effect by true luminal cells
(Epcam
+CD44
2CD49f
Lo) that co-segregated with the non-sphere-
forming basal subpopulation (Epcam
+CD44
2CD49f
Hi). Taken
together, these results suggest that the human prostate basal cell
population can be divided into populations with enriched sphere-
forming activity (Epcam
+CD44
+CD49f
Hi) or tubule-initiating
activity (Epcam
+CD44
2CD49f
Hi).
Discussion
Identifying functionally distinct populations of prostate epithe-
lial cells could provide new insights about the cells of origin for
human prostate cancer, by determining which cells within the
hierarchy are susceptible to malignant transformation. Addition-
ally, the mechanisms employed by normal prostate SCs that
enable interaction with the niche and initiation of tubule
development could lead to therapeutic approaches that interfere
with similar pathways exploited by cancer cells or contributing to
the development of benign prostatic hypertrophy (BPH). revious
studies investigating human prostate S/P cells isolated from benign
tissues have indicated that both general epithelial and basal
antigens (Trop2, CD44, alpha2beta1-integrin
Hi, alpha6-integrin
Hi
(CD49f)) are expressed [1,2,4]. In these studies, the ability to form
self-renewing prostaspheres coincides with the potential to induce
fully differentiated prostate tubules in vivo. In the current study,
subpopulations of prostate basal cells with robust sphere-forming
capability are distinguished from those with optimal tubule
initiating capability based on specific antigenic profiles. Prostate
epithelial cells with an increased potential to induce tubules
inclusive of basal and luminal cell layers (putative SCs) are
incapable of forming prostaspheres in vitro. On the other hand,
highly proliferative sphere-forming cells (putative PCs) appear to
have more limited potential for tubule initiation. This study is the
first to functionally separate prostate epithelial cells based upon
sphere-forming versus tubule initiating capabilities.
Combinations of antigens that subdivide the basal population
and functionally distinguish prostate SCs from PCs have not been
reported, with the exception of CD133, a rare surface marker
found on less than 1% of basal cells [2]. A recent report regarding
a2b1
HiCD133
+ cells indicated that these cells were incapable of
forming spheres, but readily formed proliferative monolayer
cultures [23]. Additional studies have demonstrated acinar-like
outgrowths induced by a2b1
HiCD133
+ cells, in vivo [2]. This
combined data suggests that CD133
+ cells are non-sphere-
forming, but possess SC traits of self-renewal and differentiation
capability, similar to the Epcam
+CD44
2CD49f
Hi population
reported here. In previous studies, we have also reported that
CD133 expression did not enrich for sphere-forming cells [4].
However, given the surprising new finding of increased tubule
formation induced by the non sphere-forming, Ep-
cam
+CD44
2CD49f
Hi cell fraction, analyzing concomitant expres-
sion of CD133 (and other putative SC markers) within this subset,
including further fractionation and functional analysis, should be
considered.
In previous studies of prostate S/P cells, Trop2, which has an
almost identical pattern of expression as Epcam (Trop1) within
prostate epithelial cells, was utilized to separate prostate epithelial
from stromal and blood cells [1]. One advantage of using Epcam,
as an alternative to Trop2, is stable and/or highly expressed
Epcam is detected in most adenocarcinomas, as well as metastases,
malignant effusions, and cancer stem cells [24]. Confirming the
presence of Epcam within the human prostate S/P population
may lead to investigations of therapeutic agents targeting Epcam
and evaluation of specific effects on prostate SC and PC activity
[24,25].
In the current study, CD44 expression appears to determine
whether Epcam
+ prostate epithelial cells will form robust spheres
(CD44
+) or remain quiescent in vitro, but induce robust tubule
formation in vivo (CD44
2). In the neural system, it is a well-
recognized limitation that quiescent neural SCs cannot be isolated
using the neurosphere assay [26]. Additionally, it is emphasized
that sphere-formation and self-renewal is a trait possessed by both
SCs and PCs. In the current study, the antigenic profile of cells
with the highest prostate sphere-forming capability is Ep-
cam
+CD44
2CD49f
Hi. However, sphere-forming cells marked by
Epcam
+CD44
+ expression can form tubules in vivo, but at a
statistically significant lower rate than non-sphere-forming Ep-
cam
+CD44
2 cells. Since previous in vivo studies clearly demon-
strate that CD49f
Hi is required for prostate tubule formation, we
hypothesized that the Epcam
+CD44
2CD49f
Hi antigenic profile
designates non-sphere-forming cells capable of tubule regeneration
in vivo. Indeed, this antigenic profile was confirmed in our study to
represent a subpopulation of prostate basal cells with relatively
robust tubule-initiating capability (compared to Ep-
cam
+CD44
2CD49f
Hi luminal cells) [6]. In contrast to our sphere
results, sub-fractionation of Epcam
+CD44
2 cells with increased
tubule initiation capability did not appear to further enrich for this
activity. One factor that may have contributed to this observation
is the fact that FACS sorting with three markers requires longer
sort time, which could impact the long-term viability of these cells
that is required for in vivo grafting. Despite enrichment with the
more refined cell fraction, our results clearly demonstrate an
advantage in tubule formation capability compared to luminal
Epcam
+CD44
2CD49f
Lo cells. Consequently, three distinct popu-
lations of prostate epithelial cells are revealed, including
subdivided basal (Epcam
+CD44
+CD49f
Hi and Ep-
cam
+CD44
2CD49f
Hi) and luminal (Epcam
+CD44
2CD49f
Lo)
fractions.
Bona fide SCs should be capable of residing in the quiescent
state and become activated to differentiate and form new tubules
as needed. With asymmetric cell division, progenitor daughter cells
develop with less potential to induce new tubules. In the current
study, although some sphere-forming cells retain the potential to
induce new tubules, the proportion is far less than the in vitro
quiescent Epcam
+CD44
2population. This result implies that
prostaspheres contain both SCs and rapidly proliferating progen-
itors (possible transit-amplifying cells), resulting in an overall
decreased potential to induce tubules compared to non-sphere-
forming SCs. Hence, Epcam
+CD44
HiCD49f
Hi cells may be
further along the developmental pathway and suggests a hierarchy
of prostate epithelial cells.
Although the sphere-forming assays indicate that our putative
SCs are quiescent, further studies are needed to evaluate this trait.
It has been suggested that sphere-formation is an indicator of self-
renewal, yet we have found that the non-sphere-forming
(Epcam
+CD44
2CD49f
Hi) cells are capable of inducing differen-
tiated tubules and regenerated grafts that include the full spectrum
of prostate cells found in original surgical specimens, including
putative SCs. This data indicates that in addition to differentiation
and niche interaction capabilities, the putative SCs are self-
renewing (despite the inability to form spheres).
Taken together, our results suggest that Epcam
+C-
D44
LoCD49f
Hi cells are non-sphere-forming SCs that may be
activated to form tubules when exposed to inductive stroma cells in
vivo. Lack of CD44 expression distinguishes non-sphere-forming
SCs from the more proliferative state of the CD44
+ population,
which may contain an increased proportion of PCs with limited
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CD44 as a proliferative marker exists. The majority of primary
prostate epithelial cells (transient amplifying cells) that grow as a
monolayer, in vitro, express CD44 [27,28,29]. Examination of
human prostate cancer cell lines and xenografts indicate that the
CD44
+ population is more proliferative, clonogenic, tumorigenic,
and metastatic than CD44
2 cells[30,31,32].
Future studies that may yield more insight into prostate SC/PC
characteristics and function include gene expression array analysis
comparing Epcam
+CD44
2CD49f
Hi and Epcam
+CD44
+CD49f
Hi
cells. Such efforts could reveal novel antigens and genetic
pathways that are unique to each subpopulation. Additionally,
genetic manipulation of benign prostate cell fractions based on
Epcam/CD44/CD49f expression, followed by in vivo regenera-
tion may suggest mechanisms of tumorigenesis or benign
proliferation (BPH) at different developmental stages.
Methods
Tissue Digestion and Cell Dissociation.
Human prostate tissue was obtained via a research protocol that
was approved by the Office for the Protection of Research
Subjects at UCLA and the Greater Los Angeles VA Medical
Center. Informed written consent was obtained on all participants
where identifying information was included. In cases where no
identifying information was included and tissue was acquired in an
anonymous fashion at UCLA, an approved Institutional Review
Board protocol with written consent was not required by Office for
the Protection of Research Subjects. Adjacent tissue specimens
were snap frozen in liquid nitrogen or fixed in formalin and
paraffin-embedded for histological analysis. Frozen sections were
immediately examined by a genitourinary pathologist and cancer
foci encircled. Fresh tissue specimens were matched with the
frozen section slides to enable macrodissection of benign tissue
away from tumor nodules. Typically, 2–10 grams of fresh tissue
was allocated for research studies. Tissue specimens were then
mechanically and enzymatically digested as previously described
[16]. Dissociated tissue containing single cells and organoids was
sequentially filtered through 100-mm and 40-mm cell strainer, and
then passed repeatedly through a 23-gauge needle, in order to
generate a single cell suspension. Cells were counted with a
hemocytometer and resuspended in RPMI supplemented with
10% FBS prior to cell sorting or plating in prostasphere cultures.
Approximately 1–2 million viable cells per gram of fresh tissue
were routinely obtained.
Magnetic activated cell sorting(MACS).
Miltenyi auto MACSH was used to separate Epcam
+CD44
+ and
Epcam
+CD44
2 prostate epithelial cells. For Epcam
+ cell separa-
tion, single cell suspensions obtained from freshly dissociated
prostate tissue were stained with anti-human Epcam-PE antibody
(Miltenyi Biotech), followed by incubation with anti-PE Multisort
Microbeads (Miltenyi Biotech). Stained cells were separated
through autoMACS (Miltenyi Biotech) with Mode POSSEL
(Positive Selection). Positive fraction was collected as Epcam
+ cells
and microbeads were removed using Multisort Release Reagents
(Miltenyi Biotech). Cells were then stained with CD44 microbeads
before separation through auto MACSH separator with POSSEL,
with collection of positive (Epcam
+CD44
+) and negative (Ep-
cam
+CD44
2) fractions. The negative fraction was separated
further with Mode DEPLETES (Depletion in sensitive mode.
The Epcam
+CD44
+ and Epcam
+CD44
2 cells were stained with
anti-human CD44-PE-Cy-7 (eBioscience) and analyzed by FACS
to evaluate the purity of sorted cells.
Fluorescence-activated cell sorting (FACS).
Prostate cells were suspended in PBS, 2 mM EDTA,0.5%BSA
and stained with antibody for 15 minutes at 4uC. Fluorescence-
activated cell sorting and analysis were performed on a BD Special
Order FACS Aria II system and Diva v6.1.1 (BD Biosciences).
Live single cells were gated based on scatter properties and
analyzed for their surface marker expression. Cells were sorted
and collected at 4uC using 100um nozzle and 23psi. Antibodies
used for FACS include Epcam-PE (Miltenyi Biotech), CD44-FITC
(ebioscience), and CD49f-APC (BioLegend).
In vitro prostasphere assay.
Prostate cells were counted and re-suspended in 50:50 Matrigel:
PrEGM with a concentration of 5610
3 cells/80microliters. This
Matrigel/cellular suspension was plated at the edge of the well on
12-well plates and allowed to solidify by incubation at 37uC for
30 minutes. One milliliter of defined sphere media was then added
to each well and plates were replaced in 37uC incubator, as
previously described [4]. Quantitation of prostaspheres was
performed approximately 10–14 days after plating.
Tissue acquisition, isolation and culture of fetal prostate
cells.
Human fetal prostate tissue was acquired from 16–17 week
specimens in accordance with federal and state guidelines.
Adjacent prostate tissue was snap frozen in liquid Nitrogen or
fixed in formalin and paraffin-embedded to evaluate anatomy and
glandular architecture. The remainder of the tissue was mechan-
ically and enzymatically digested as described (13). Dissociated
prostate cell suspensions were sequentially filtered through 100-
micron and 40-micron filters, and then passed through a 23-gauge
needle. Cells were counted with a hemocytometer and resus-
pended in RPMI supplemented with 10% fetal bovine serum
(FBS), penicillin/streptomycin (Mediatech Inc.), and Methyltrie-
nolone R1881 (Sigma) for culture in vitro. After 3 passages, cells
were analyzed via FACS to confirm purity of stromal cells (See
below). HFBS is cryopreserved and thawed as needed for use in
recombination assays.
In vivo tissue regeneration.
In vivo tissue experiments were performed in male SCID-
NOD
IL2grNULL mice in accordance with protocol number 2007-
189-11A, approved by the Animal Research Committee within
the Office for the Protection of Research Subjects at UCLA. Mice
(6–8 weeks old) were subjected to subcutaneous injections of
prostate epithelial cells. Approximately 1610
5 epithelial cells were
combined with 2610
5 primary human fetal prostate stroma cells
(hFPS). The epithelial and stromal cells were then suspended in
50 microliters 50:50 MatrigelH: PrEGM. Subcutaneous implan-
tation of time-release testosterone pellets (Innovative Research of
America) was simultaneously performed at the time of graft
implantation. Subcutaneous nodules at the site of injection were
removed after approximately 12 weeks of the implantation and
frozen/paraffin-embedded sections were generated for immuno-
histochemical analysis. Fresh hFPS cells were cultured in RPMI
supplemented with 10% FBS and R1881 (Sigma) and passaged
three times prior to use in tissue regeneration assays.
Immunohistochemistry of tissue sections.
Prostate tissue was paraffin embedded as previously described
[33]. Four-micron thick sections of frozen or paraffin embedded
tissue were deparaffinized with xylene and rehydrated through a
descending series of ethanol washes as described [4]. Antigen
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combination with primary antibodies, including CK5, CK8
(Convane), p63, androgen receptor (AR), Prostate Specific Antigen
(PSA) (Santa Cruz), and CD44 (Abcam).
Real time RT-PCR Analysis.
RNA was extracted using Qiagen RNAeasy Micro Kit,
following the manufacturer’s instructions. The concentration and
purity of total RNA was assessed spectrophotometrically at 260
and 280 nm. CDNA was generated from total RNA (up to 5 mg)
using SuperScript III First-Strand Synthesis Kit (Invitrogen). For
quantitative Real-time PCR, a Bio-Rad CFX Multicolor Real-
time PCR detection system was employed, using the SYBRH-
Green Supermix (Bio-Rad Laboratories). Real-time PCR primer
pairs for CK8, PSA, AR and p63 were purchased from
SABiosciences Corporation. The PCR reaction conditions includ-
ed an initial step at 95uC for 3 min, followed by 40 cycles at 95uC
for 15 s (Melt) and 60uC for 45 s (Anneal/Extend). Detection of
PCR products was accomplished by measuring the emitting
fluorescence at the end of each reaction step (reaction cycles).
Threshold cycle corresponds with the cycle number required to
detect a fluorescence signal above the threshold. Calculations were
performed by Bio-Rad IQ5 software provided by the manufac-
turer. Gene expression analysis was performed using the
comparative method.
Supporting Information
Figure S1 Comparison of prostate tissue grafts induced
by rUGSM and hFPS. Total adult prostate cells (5610
5) isolated
from fresh benign surgical specimens were combined with either
rUGSM or hFPS (1610
6 cells). Grafts were retrieved approxi-
mately 12 weeks following subcutaneous injection into SCID-
NOD
IL2crNULL mice. H&E staining of paraffin-embedded sections
demonstrated similar composition of tubular structures within
grafts, including ductal/acini structures, corpora amylacea, and
epithelial cords. Similar to previous studies with rUGSM, grafts
that formed from hFPS without additive adult prostate epithelial
cells (PCs) did not contain any tubular structures. All grafts with
tubules (T) were found to have prominent vasculature (BV)
throughout (Right panel).
(TIF)
Figure S2 Table depicting number of patient samples
utilized for implants and grafts retrieved. A total of 29
implants yielded 20 grafts with tubules for comparative analysis
(69% engraftment rate).
(TIF)
Figure S3 Epcam (Trop1) and Trop2 demonstrate
overlapping expression in human prostate cells, while
CD49f and CD44 demonstrate disparate expression. A.
Total prostate cells were co-stained with antibodies recognizing
Epcam and Trop2 and subjected to FACS analysis. The majority
of Epcam
+ cells co-expressed Trop2. B. Total prostate cells were
co-stained with antibodies recognizing CD44 and CD49f. A
population of CD49f
Hi cells were identified that appear to be
CD44
2, suggesting that a proportion of Epcam
+CD44
2cells may
co-express CD49f.
(TIF)
Figure S4 FACS analysis of individual patient surgical
specimens for Epcam/CD44/CD49f. Four patient speci-
mens (A–D) are shown for comparative analysis of populations
retrieved. After mechanical and enzymatic digestion, single cell
suspensions are stained with antibodies targeting Epcam, CD44,
and CD49f. High and low CD44-expressing populations of
Epcam+ cells are gated and analyzed for CD49f expression. High
and low CD49f-expressing cells are then isolated for functional
analysis.
(TIF)
Figure S5 Quantitative RT-PCR demonstrates Ep-
cam
+CD44
2CD49f
Hi cell fractions have a basal profile
(p63
+AR
LoPSA
2), while Epcam
+CD44
2CD49f
Lo cells dis-
play a luminal profile (p63
LoAR
HiPSA
+). Primers targeting
p63, AR, and PSA were used in fractionated cells to compare
expression relative to unfractionated cells (U). Ep-
cam
+CD44
2CD49f
Hi (+/2/H), Epcam
+CD44
2CD49f
Lo (+/2/
L). Statistical analysis was performed using standard one-way
ANOVA analysis. P,0.05(*), P,0.01(**).
(TIF)
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